GlassScriptPhysician profile
David A Escalante
NPI 1427096551
$326,296.12
in general payments reported to CMS, 2019-2025
43 companies · $34K in 2025
The $34K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121K · 2020: $26K · 2021: $42K · 2022: $24K · 2023: $18K · 2024: $61K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Honoraria: $15K · Food and Beverage: $6,343 · Travel and Lodging: $2,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,700.00 |
| Honoraria | $15,105.00 |
| Food and Beverage | $6,342.99 |
| Travel and Lodging | $2,958.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $91,382.25 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $84,843.47 | 2019-2023 | |
| Lilly USA, LLC | $82,734.51 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $46,748.84 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $9,809.34 | 2019-2020 | |
| Mannkind Corporation | $6,010.27 | 2019-2025 | |
| Medtronic, INC. | $673.10 | 2022-2025 | Minimed 780g |
| Abbvie INC. | $549.71 | 2019-2025 | |
| Insulet Corporation | $373.79 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $352.42 | 2019-2022 | |
| Novo Nordisk INC | $317.30 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Recordati_rare_diseases_inc. | $258.66 | 2024-2025 | Isturisa |
| Dexcom, INC. | $252.32 | 2020-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $219.61 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Cequr Corporation | $144.59 | 2024-2025 | Cequr Simplicity |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $135.70 | 2019-2025 | Tepezza, Evenity, Prolia |
| Amryt Pharma Holdings LTD | $128.41 | 2022-2023 | Mycapssa |
| Bayer Healthcare Pharmaceuticals INC. | $124.69 | 2022-2025 | |
| Abbott Laboratories | $114.96 | 2021-2025 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $96.29 | 2022-2023 | Crysvita |
| Millicent US INC | $92.22 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Astellas Pharma US INC | $85.59 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $79.17 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Tandem Diabetes Care, INC. | $74.83 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $70.52 | 2022-2023 | |
| Horizon Therapeutics Plc | $64.43 | 2022-2023 | Tepezza |
| Janssen Pharmaceuticals, INC | $59.35 | 2022 | |
| Shire North American Group INC | $59.30 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.92 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $52.52 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.96 | 2021-2022 | |
| Amphastar Pharmaceuticals, INC. | $39.37 | 2025 | |
| Opko Pharmaceuticals, LLC | $34.81 | 2023 | Rayaldee |
| Exact Sciences Corporation | $29.29 | 2025 | The Cologuard Plus Collection Kit |
| Intra-Sana Laboratories | $28.48 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Sequel Med Tech, LLC | $27.48 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $23.28 | 2025 | Yorvipath |
| Mayne Pharma Commercial LLC | $20.39 | 2025 | |
| Chiesi USA, INC. | $20.25 | 2024 | Mycapssa |
| Takeda Pharmaceuticals U.S.A., INC. | $19.49 | 2020 | |
| Ascensia Diabetes Care US INC. | $17.30 | 2023 | |
| Averitas Pharma INC. | $16.16 | 2025 | Qutenza |
| Kowa Pharmaceuticals America, INC. | $12.78 | 2023 | Seglentis, Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Escalante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.